Range Cancer Therapeutics ETF (CNCR) Short Interest Ratio & Short Volume

Short interest is the volume of Range Cancer Therapeutics ETF shares that have been sold short but have not yet been closed out or covered. As of March 15th, traders have sold 6,800 shares of CNCR short. 0.87% of Range Cancer Therapeutics ETF's shares are currently sold short. Learn More on Range Cancer Therapeutics ETF's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CNCR shares currently have a short interest ratio of 2.0. Learn More on Range Cancer Therapeutics ETF's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.87% of Range Cancer Therapeutics ETF's floating shares are currently sold short.

Range Cancer Therapeutics ETF saw a increase in short interest in March. As of March 15th, there was short interest totaling 6,800 shares, an increase of 6.3% from the previous total of 6,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.87% of Range Cancer Therapeutics ETF's shares are currently sold short. Here is how the short interest of companies compare to Range Cancer Therapeutics ETF: JPMorgan Healthcare Leaders ETF (0.07%), ProShares UltraShort Nasdaq Biotechnology (3.50%), First Trust Nasdaq Pharmaceuticals ETF (0.10%), Invesco Nasdaq Biotechnology ETF (0.10%), ProShares Ultra Nasdaq Biotechnology (0.20%), Invesco Dorsey Wright Healthcare Momentum ETF (0.39%), VanEck Biotech ETF (0.13%), VanEck Pharmaceutical ETF (41.19%), and iShares Biotechnology ETF (20.78%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks.

Short selling CNCR is an investing strategy that aims to generate trading profit from Range Cancer Therapeutics ETF as its price is falling. CNCR shares are trading down $2.54 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Range Cancer Therapeutics ETF occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CNCR, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CNCR, twice per month. The most recent reporting period available is March, 15 2025.